Amgen is investing $1 billion for a second factory in North Carolina after already allocating more than half a billion dollars for a separate facility in the state.

The race to create the next best medication for obesity is well underway, and the incumbents are doing everything they can to shore up manufacturing, fight the compounders and develop ...

TORL BioTherapeutics, the antibody-drug conjugate startup led by former Celgene chief Mark Alles, has brought aboard a chief medical officer with big pharma chops. Aran Maree will be overseeing ...

The FDA is hoping its latest solution will stave off the continued shortage of cisplatin, a key drug used in treating several types of cancer. Beginning ...

Small molecule biotech Totus Medicines has closed a $66 million Series B to carry its PI3Kα inhibitor through Phase Ia and has named Nassim Usman as its new president and ...

House Re­pub­li­cans take is­sue with DO­J's han­dling of Mod­er­na's Covid vac­cine patents ...

To help meet the heightened demand for its injectable products, Eli Lilly is acquiring a facility from Nexus Pharmaceuticals, with production anticipated to start at the end of next year ...

Novartis and BeiGene have mutually agreed to axe their collaboration on a Phase III TIGIT inhibitor, marking another derailment in a field once thought to be the next immunotherapy breakthrough ...

The FDA recently added a new warning and precaution to the label of Horizon's blockbuster monoclonal antibody Tepezza (teprotumumab-trbw), which is used as a treatment for thyroid eye disease, to ...

Below are notable updates from the American Academy of Dermatology’s annual meeting over the weekend: Sanofi amends trial protocol Sanofi has big plans for amlitelimab, the monoclonal antibody ...

A pair of late-stage biotechs submitted IPO plans last week as industry insiders gear up for what could be a handful of post-Labor Day public debut pitches. To repeat: That ...

Manchester, UK-based F2G has patched together another $100 million in funding a little over a year after receiving a CRL for its experimental fungal infection drug known as olorofim, it ...